Angela M Cacace, the Chief Scientific Officer of $ARVN, sold 4,592 shares of the company on 02-13-2026 for an estimated $54,598. We received data on the trade from a recent SEC filing. This was a sale of approximately 2.9% of their shares of this class of stock. Following this trade, they now own 151,232 shares of this class of $ARVN stock.
$ARVN Insider Trading Activity
$ARVN insiders have traded $ARVN stock on the open market 5 times in the past 6 months. Of those trades, 1 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $ARVN stock by insiders over the last 6 months:
- BRIGGS MORRISON purchased 30,000 shares for an estimated $227,010
- NOAH BERKOWITZ (Chief Medical Officer) sold 5,685 shares for an estimated $67,594
- ANGELA M CACACE (Chief Scientific Officer) sold 4,592 shares for an estimated $54,598
- DAVID K LOOMIS (Chief Accounting Officer) has made 0 purchases and 2 sales selling 1,246 shares for an estimated $14,354.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ARVN Hedge Fund Activity
We have seen 99 institutional investors add shares of $ARVN stock to their portfolio, and 135 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- LOGOS GLOBAL MANAGEMENT LP removed 5,575,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $66,119,500
- POINT72 ASSET MANAGEMENT, L.P. added 2,315,361 shares (+inf%) to their portfolio in Q4 2025, for an estimated $27,460,181
- CAPTION MANAGEMENT, LLC removed 1,343,029 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $11,442,607
- VANGUARD GROUP INC removed 1,331,629 shares (-15.6%) from their portfolio in Q4 2025, for an estimated $15,793,119
- TCG CROSSOVER MANAGEMENT, LLC added 1,048,851 shares (+64.8%) to their portfolio in Q4 2025, for an estimated $12,439,372
- TWO SIGMA INVESTMENTS, LP added 992,463 shares (+inf%) to their portfolio in Q4 2025, for an estimated $11,770,611
- OPALEYE MANAGEMENT INC. removed 987,818 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $11,715,521
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ARVN Analyst Ratings
Wall Street analysts have issued reports on $ARVN in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stephens & Co. issued a "Overweight" rating on 11/10/2025
- BTIG issued a "Buy" rating on 09/18/2025
To track analyst ratings and price targets for $ARVN, check out Quiver Quantitative's $ARVN forecast page.
$ARVN Price Targets
Multiple analysts have issued price targets for $ARVN recently. We have seen 6 analysts offer price targets for $ARVN in the last 6 months, with a median target of $15.0.
Here are some recent targets:
- Yigal Nochomovitz from Citigroup set a target price of $15.0 on 01/06/2026
- Etzer Darout from Barclays set a target price of $18.0 on 12/17/2025
- Sudan Loganathan from Stephens & Co. set a target price of $15.0 on 11/10/2025
- Derek Archila from Wells Fargo set a target price of $15.0 on 11/06/2025
- Jeet Mukherjee from BTIG set a target price of $14.0 on 10/30/2025
- Paul Choi from Goldman Sachs set a target price of $6.0 on 10/15/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
